News
NMRA
0.5962
-12.01%
-0.0814
Weekly Report: what happened at NMRA last week (0921-0925)?
Weekly Report · 2d ago
Weekly Report: what happened at NMRA last week (0914-0918)?
Weekly Report · 09/21 09:23
Weekly Report: what happened at NMRA last week (0907-0911)?
Weekly Report · 09/14 09:24
Weekly Report: what happened at NMRA last week (0831-0904)?
Weekly Report · 09/07 09:22
Weekly Report: what happened at NMRA last week (0824-0828)?
Weekly Report · 08/31 09:24
Insiders Sold Neumora Therapeutics Prematurely At US$2.29 With Stock Trading Higher
Simply Wall St · 08/29 12:00
Weekly Report: what happened at NMRA last week (0817-0821)?
Weekly Report · 08/24 09:24
Top Neumora Executive Makes Notable Move With Insider Stock Sale
TipRanks · 08/22 02:05
Neumora Therapeutics, Inc. (NMRA) Receives a Buy from RBC Capital
TipRanks · 08/18 02:25
Neumora CEO transition not a surprise, says H.C. Wainwright
TipRanks · 08/17 15:50
Weekly Report: what happened at NMRA last week (0810-0814)?
Weekly Report · 08/17 09:25
Neumora Therapeutics CEO Paul Berns to switch roles, Joshua Pinto to succeed
TipRanks · 08/16 13:42
Neumora Therapeutics, Inc. (NMRA) Receives a Rating Update from a Top Analyst
TipRanks · 08/14 16:35
Analysts Offer Insights on Healthcare Companies: Neumora Therapeutics, Inc. (NMRA), Celcuity (CELC) and Parabilis Medicines, Inc. (PBLS)
TipRanks · 08/14 16:30
Neumora Q2 Loss Narrows, Advances CNS Pipeline; Names Joshua Pinto CEO
NASDAQ · 08/14 13:46
Neumora Therapeutics Announces CEO Transition and Q2 Results
TipRanks · 08/14 11:28
Neumora Therapeutics Promotes Pinto to CEO
Dow Jones · 08/14 11:26
Neumora Therapeutics GAAP EPS of -$0.23 beats by $0.01
Seeking Alpha · 08/14 11:09
*Neumora Therapeutics: Co-founder Paul L. Berns Will Serve as Executive Chair
Dow Jones · 08/14 11:02
*Neumora Therapeutics Names Joshua Pinto Pres and CEO
Dow Jones · 08/14 11:01
More
Webull provides a variety of real-time NMRA stock news. You can receive the latest news about Neumora Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About NMRA
Neumora Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutic pipeline consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of depressive disorder (MDD). Navacaprant is being investigated in the KOASTAL pivotal Phase 3 program, evaluating navacaprant monotherapy in patients with moderate to severe MDD. The Company's next advanced product candidate is NMRA-511, which is a highly selective, novel antagonist of the vasopressin 1a receptor (V1aR) being developed for the treatment of agitation associated with dementia due to Alzheimer's disease (AD).